Meeting
2017 ASCO Annual Meeting
Tumor kinetic modeling and identification of predictive factors for tumor response to durvalumab in patients with non-small cell lung cancer (NSCLC).
Authors
Yanan Zheng
MedImmune, Mountain View, CA
Yanan Zheng , Rajesh Narwal , Chaoyu Jin , Bing Wang , Xiaoping Jin , Pralay Mukhopadhyay , Brandon W. Higgs , Ashok Kumar Gupta , Phillip A. Dennis , Lorin Roskos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Immunobiology
Clinical Trial Registration Number
NCT02087423 and NCT01693562
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11555)
DOI
10.1200/JCO.2017.35.15_suppl.11555
Abstract #
11555
Poster Bd #
255
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab.
First Author: Thomas Powles
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2017 ASCO Annual Meeting
IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.
First Author: Howard Jack West
Poster
2016 ASCO Annual Meeting
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.
First Author: Scott Joseph Antonia